1. Search Result
Search Result
Results for "

LC2

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137516
    LC-2
    1 Publications Verification

    PROTACs Ras Cancer
    LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM . LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines [2].
    <em>LC-2</em>
  • HY-139402

    Ras Cancer
    MRTX849 acid, a derivative of MRTX849, can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50s between 0.25 and 0.76 μM) [2].
    MRTX849 acid
  • HY-P3965

    Myosin Neurological Disease
    16-38-Thymosin β4 (cattle) is a Ca 2+-independent MLCK activator with high affinity .
    16-38-Thymosin β4 (cattle)
  • HY-137516A

    PROTACs Ras Cancer
    LC-2 epimer is a differential isomer of LC-2. LC-2 is a mutation-selective PROTAC depressant for KRAS and contains a ligand for the von Hippel Lindau E3 ligase linked to the KRAS inhibitor MRTX849 .
    <em>LC-2</em> epimer
  • HY-139403

    Target Protein Ligand-Linker Conjugates Ras Cancer
    MRTX849 ethoxypropanoic acid incorporates a ligand for KRAS G12C, and a PROTAC linker. MRTX849 ethoxypropanoic acid can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (IC50s between 0.25 and 0.76 μM) [2].
    MRTX849 ethoxypropanoic acid
  • HY-P3965A

    Myosin Neurological Disease
    16-38-Thymosin β4 (cattle) TFA is a Ca 2+-independent MLCK activator with high affinity .
    16-38-Thymosin β4 (cattle) (TFA)
  • HY-144131

    Apoptosis RET Cancer
    RET-IN-11 is a potent and selective RET inhibitor with IC50s of 6.20 nM, 18.68 nM for RET and RET V804M, respectively. RET-IN-11 shows anti-proliferation and migration activity in CCDC6-RET-driven LC-2/ad cells. RET-IN-11 induces cell apoptosis .
    RET-IN-11
  • HY-133551

    RET Cancer
    WF-47-JS03 is a potent and selective RET kinase inhibitor with IC50s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR). Effective brain penetration .
    WF-47-JS03

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: